SB 173 is titled "Prohibiting abortifacients" and, based on its caption and legislative history, appears to restrict the manufacture, sale, distribution, prescribing, or use of drugs or other substances intended to induce abortion. Because the bill text was not available in the provided materials, the precise statutory changes cannot be quoted, but the measure is clearly aimed at limiting access to abortion-inducing medications and related products in West Virginia.
The bill passed the West Virginia Senate on February 13, 2026, by a wide margin of 29-1 and was then sent to the House Judiciary Committee. That vote suggests strong support in the Senate for the bill’s general policy direction. The absence of committee transcript material means there is no recorded debate here on implementation details, exceptions, or enforcement mechanisms, but the caption indicates the bill would likely affect providers, pharmacies, manufacturers, and patients seeking medication abortion.
Impact
SB 173 would likely amend West Virginia law governing controlled or regulated medical products by creating new restrictions on abortifacients and potentially related abortion-inducing drugs. Depending on the final text, it could affect prescribing practices, pharmacy dispensing, medical liability, and enforcement authority for state regulators or prosecutors. The bill’s practical impact would be to narrow access to medication abortion and impose compliance obligations on healthcare providers and distributors.
Sentiment
The available voting history shows strong support for the bill in the Senate, with only one dissenting vote, indicating generally favorable sentiment among senators toward the proposal. No committee discussion was provided, so there is no direct record here of stakeholder testimony or detailed objections. The overall tone from the legislative record available is that the measure advanced with little visible resistance in the chamber where it was considered.
Contention
The central point of contention is the bill’s restriction of abortifacients, which implicates abortion access, reproductive rights, and the regulation of medication abortion. Supporters are likely to frame the bill as protecting unborn life and limiting abortion through drugs, while opponents would likely argue it interferes with patient access to lawful medical care and burdens physicians and pharmacies. Because no transcript was provided, specific disputes over exceptions for rape, incest, medical emergencies, or enforcement provisions cannot be confirmed from the record here.